Navigating Treatment Options in Low-Risk Myelodysplastic Syndromes

Researchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.